Based on the above molecular and biological findings, targeting IL-5 as a therapeutic strategy is highly rational from a pathophysiological perspective and is now regarded as an indispensable approach in the treatment of EGPA. This evidence concerns the gene IL5 and eosinophilic granulomatosis with polyangiitis.